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for hypertrophic cardiomyocytes by acting on histone acetylation
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Received April 8, 2014; accepted September 23, 2014AbstractBackground: Chronic heart failure (CHF) is a complex clinical syndrome, and a serious stage of various heart diseases. Dysfunction of histone
acetylation is involved in pathogenesis of CHF. Lujiao is a clinical and traditional prescription that has been previously used in the treatment of
heart failure. The objective of our study was to explore the effects of traditional Chinese Medicine intervention with Lujiao prescription on
hypertrophic cardiomyocytes with histone acetylation abnormality.
Methods: Myocardial cells from neonatal rats were stimulated via phenylephrine (PE) and then randomly divided into seven groups: normal
group (without any treatment), model group (treated with saline), TSA group (treated with trichostatin A), perindopril group (treated with
perindopril), and the high, medium, and low dose of Lujiao groups (treated with 2.4 g/mL, 1.2 g/mL, and 0.6 g/mL of Lujiao, respectively). The
test drug of perindopril group or Lujiao group was derived from serum after drug treatment in rats. Real-time polymerase chain reaction and
Western blot were performed to analyze expression of myocyte enhancer factor 2 (MEF-2), a-major histocompatibility complex (MHC), and b-
MHC and acetylation level of histone H3.
Results: Expressions of MEF-2 and b-MHC were significantly increased after PE treatment and decreased after drug treatment. Expression of a-
MHC mRNAwas significantly reduced after PE treatment and increased after being treated with Lujiao prescription, perindopril, and TSA. The
acetylation level of histone H3 decreased in rat myocardial cells stimulated by PE 48 for hours and this decrease was reversed after treatment
with high and medium doses of Lujiao prescription, perindopril and TSA.
Conclusion: Histone acetylation-MEF-2-a-MHC/b-MHC axis was discovered in myocardial hypertrophy, and intervention of Lujiao prescription
exhibited good effects.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assstage of various heart diseases.1 According to epidemiological
data released in 2003, the average prevalence rate of heart
failure in China was 0.9% (age 35e74 years).2 In addition, the
exorbitant costs as a result of long-term treatment and repeated
exacerbations and hospital costs have become a burden of
families and society, and increasingly represent a serious
global public health problem.1,2
CHF treatment decisions have changed from an emphasis
on short-term, hemodynamic/pharmacological measures to a
long-term maintenance and repair strategy.3 Efforts to repair
failed myocardial biology, blocking of the vicious spiralociation. All rights reserved.
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myocardial remodeling have become the key for treatment of
CHF. American Heart Association/American College of
Cardiology heart failure guidelines classify the high-risk
population of CHF and the refractory heart failure patients
into four stages (AeD) according to the process of the
development of CHF, and provides comprehensive preven-
tion treatment in different stages.4 Nevertheless, in the face
of a rising prevalence rate, the continued decline of high-
risk-of-death and hard-to-reverse malignant diseases, CHF
treatment is still an ongoing challenge. Not only do the
symptoms and prognosis of the diseases need to be
improved, but also new drugs with fewer side effects or
treatment are urgently needed.3,4
It is well known that myocardial remodeling is the basic
mechanism of the occurrence and development of heart
failure, including hypertrophy and apoptosis of car-
diomyocytes, myocardial extracellular matrix quality, and
composition change.5 In the development of CHF, the sym-
pathetic activation and long-term pressure overload is an
important cause of myocardial remodeling, and cardiac hy-
pertrophy is one of the most important myocardial remod-
eling elements in the pathological process.6 Focusing on
myocardial cell hypertrophy, an important pathological pro-
cess, there are clinical and social significances for the further
study of the pathogenesis and intervention of myocardial
hypertrophy.2,5,6
The present study will innovatively introduce histone
acetylation modification to explore the role of traditional
Chinese medicine intervention during myocardial hypertro-
phy. Many investigations revealed that altered expression of
b-major histocompatibility complex (MHC) was observed in
CHF hypertrophy myocardial cells in compensatory stage
with the force of contraction, with decreased a-MHC/b-MHC
ratio.7e9
Class II histone deacetylase (HDAC2) regulates histone
deacetylase myocyte enhancer factor 2 (MEF-2) to prevent
myocardial cell hypertrophy10; acetyl transferase P300 and
histone acetyltransferases (HATs-p300) promote cardiac hy-
pertrophy combined with MEF-2 after histone acetylation.11
The transcription factor MEF-2 shows activity only in the
adult human heart, but it is reported that MEF-2 activity
increases rapidly in the hypertrophy of cardiomyocytes
induced by calcium dependent stimulation signal under
stress.5 MEF-2 provides a correlation between HDACs,
HATs, and downstream response genes (such as myocardial
hypertrophy of embryonic gene), and it also plays positive or
negative roles in gene expression of pathological myocardial
cells.12
Lujiao prescription is a clinical and traditional prescription
in the treatment of heart failure, and is mainly composed of
antler, epimedium, psoralea fruit, dogwood, glossy privet fruit,
and dried tangerine or orange peel.13 The function of Lujiao
prescription is to nourish Yin and Yang, warm the kidney, and
strengthen the heart. The benefit effects of Lujiao prescription
are apparent primarily through positive constriction, dilation
of blood vessels, and a creation of a diuretic result.13 Themedicine can promote the influx of extracellular calcium,
reduce plasma atrial natriuretic peptide (ANP), angiotensin II
(AngII), and aldosterone concentrations, and reduce left ven-
tricular regional AngII levels and angiotensin receptor I
mRNA expression. Furthermore, the medicine can block and
reverse ventricular remodeling process to a certain extent, and
significantly improve the symptoms of heart failure without
obvious side effects.2,10,12e16
In the present study, neonatal rat cardiomyocytes were
cultured in vitro, and hypertrophied myocardial cell culture
models were constructed. Lujiao prescription was used to
intervene in the hypertrophy of cardiac muscle cells to explore
the mechanism of Lujiao prescription from the histone acet-
ylation avenue.
2. Methods2.1. Ethical approval of studiesAll studies have been approved by the Ethics Committee of
Shanghai Shuguang Hospital Affiliated with Shanghai Uni-
versity of Traditional Chinese Medicine, Shanghai, China and
performed in accordance with proper ethical standards.2.2. Lujiao prescriptionLujiao prescription was bought from the Traditional Chi-
nese Medicine Pharmacy in Shuguang Hospital. Raw materials
of Lujiao prescription by weight percent were as follows:
1e5% deerhorn glue or 8e25% antlers, 15e40% Epimedium,
15e40% Fructus Ligustri Lucidi, 10e30% Fructus Psoraleae,
8e25% Fructus Corni, and 8e25% orange. According to the
above proportion, antler glue or crushed antlers were prepared
via 80 mesh sieving. About 10e30 times the amount of water
was added to the remaining components. The solution was
boiled at 90 ± 10C two or three times (1.5 h for each time).
After filtering, the decoction was merged to a concentration
with the relative density of 1.04e1.05 at room temperature.
After high-speed centrifugation 289,249g, the supernatant was
concentrated to a relative density of 1.10e1.14 at 90C. Spray
drying or the addition of a small amount of dextrin spray was
used to dry and extract the powder. The above antler powder
and the extracted powder mixture were added to the medicinal
materials according to the conventional methods of granular
preparation. The particles were dissolved in water before use,
with a crude drug concentration of 1.2 g/mL.2.3. Perindopril (tablets)Perindopril tablets (4 mg/tablet) were used in the present
study. The perindopril (tablets) were produced by French
pharmaceutical company Servier Pharmaceutical (Suresnes,
France). The tablets were crushed and subjected to a phar-
macopoeia 100 mesh sieve, and then added into twice distilled
water with an 0.5% suspension agent (sodium carboxymethyl
cellulose). Finally, a 0.036 mg/mL concentration of peri-
ndopril suspension was produced.
488 W. Zhao et al. / Journal of the Chinese Medical Association 78 (2015) 486e4932.4. Drug administration and serum samples collectionMale SpragueeDawley (SD) rats (body weight 220e300 g,
Shanghai SLRC Laboratory Animals Co., Shanghai, China)
were fasted for 12 hours, and then randomly divided into the
following groups: normal control group treated with vehicle;
perindopril group treated with perindopril; the high, medium,
and low dose of Lujiao groups treated with high, medium, and
high dose of Lujiao, with 12 rats in each group. For experi-
ments involving animals, approval was obtained from the
Institutional Review Board of the Shanghai Shuguang Hospital
Affiliated with Shanghai University of Traditional Chinese
Medicine. According to the human and animal surface area of
the equivalent dose conversion ratio table conversion, the
concentrations of Lujiao in high, medium, and low dose of
Lujiao groups were 2.4 g/mL, 1.2 g/mL, and 0.6 g/mL,
respectively. The Lujiao prescription or perindopril was dis-
solved in water solvent and administrated by gavage. In the
normal control group, double distilled water was administered.
Drugs were used with a volume of 100 mL/g of body weight
two times/d for 7 continuous days. At 2 hours after the last
drug administration, ether anesthesia was conducted.
Abdominal aortic blood was collected under aseptic condi-
tions. After resting in a sterile tube for 4 hours, the samples
were centrifuged at 13,282g for 15 minutes, and then serum
was collected. The protein concentration of the serum was
measured for the purpose of quality control by absorbance
value measurement using spectrophotometry via an enzyme-
linked immunosorbent assay reader. The serum of the same
group was mixed and inactivated at 56C for 30 minutes to
eliminate interference of virus and other factors. After the
samples were packed, they were frozen at 80C until
analysis.2.5. Myocardial cell culture and packet processingMethods of myocardial cell culture and packet processing
were used according to the literature.17 Ten neonate SD ratsFig. 1. Different treatment(P2-3, provided by Shanghai SLRC Laboratory Animals Co.,
Shanghai, China) were soaked in 0.1% bromogeramine. The
hearts were quickly collected, and placed into petri dishes
containing 5 mL Dulbecco's modified Eagle medium
(DMEM). The atria and great vessels were trimmed, and the
residual blood washed away. The apical portion was put in
another petri dish. Then, the apical part was quickly cut into
1 mm3 pieces and transferred into an Erlenmeyer flask with
5 mL trypsin and incubated in a 34C water bath for 10 mi-
nutes. The supernatant was transferred into a centrifuge tube,
and centrifuged at 944g for 10 minutes. The residue was then
added to 5 mL of trypsin and incubated at 34C in a water bath
for 10 minutes. After that, the supernatant was transferred to
another tube and centrifuged at 944g for 10 minutes. If there
were residual tissues, the above procedures were repeated two
to three additional times. The collected digestive supernatant
was centrifuged at 4C at 1475g, after which the supernatant
was removed. Cell pellets were washed with liquid suspension
culture of DMEM containing 10% fetal bovine serum (Gibco,
Grand island, N.Y., USA). The cells were cultured in cell
culture flasks for 90e100 minutes in 5% CO2, 37
C, and in
high humidity. Then nonadherent myocardial cell suspension
was carefully aspirated and divided into 7 groups (Fig. 1).
Phenylephrine (PE, final concentration 20mM, Sigmae
Aldrich Co., St Louis, MO, USA) was added in the cultured
myocardial cells to establish myocardial hypertrophy cell
model. The expression of ANP was detected by real time
polymerase chain reaction (PCR) to test whether the model
was successfully established. Cell diameters were also
detected using the cell imagine analysis system (CAIS-1000;
China Daheng Group, Beijing, China) to record volume
changes. Trichostatin A (TSA, final concentration of 100nM;
Wako, Osaka, Japan) served as a positive control. Different
treatments were administrated to the separated groups, as
shown in Fig. 1. In the normal control group and model group,
an equal amount of DMEM was added. All cells were co-
cultured for 48 hours for further real-time PCR or Western
blot analysis.s for different groups.
Table 1
Real-time polymerase chain reaction primers.













MEF-2 ¼ myocyte enhancer factor-2; MHC ¼ major histocompatibility
complex.
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quantitative PCRThe conventional TRIzol method (Invitrogen) was used to
extract the total RNA of myocardial cells and real-time
quantitative PCR was employed for analysis. Expressions of
MEF-2, a-MHC, and b-MHC mRNAwere determined with b-
actin as internal reference. The primers used in this analysis
are listed in Table 1.2.7. Immunoblotting detection of histone H3 acetylationWestern blot was conducted to detect the expression of
histone H3 acetylation according to earlier studies.18 Primary
antibodies against MEF-2, a-MHC, and b-MHC, as well as
secondary antibodies against goat-anti mouse-HRP (Sigma)
were used.2.8. Statistical analysisExperimental data were expressed as mean ± standard
deviation. Mean comparisons were compared with one-way
analysis of variance (ANOVA), followed by use of the Bon-
ferroni t test for multiple comparisons between groups. A p
value <0.05 indicated that the difference was statistically
significant. In order to facilitate the display and analysis, the
data of the control group were set to 1, and the data of other
groups were calculated by comparison with the control group.Fig. 2. Establishment of myocardial hypertrophy model via PE. (A) Cell diameters
polymerase chain reaction showed that there was increased expression of ANP befor
a marker for myocardial hypertrophy. ANP ¼ atrial natriuretic peptide; con ¼ con3. Results3.1. Establishment of the myocardial hypertrophy cell
modelPE was added into the cells to establish the myocardial
hypertrophy model (after the stimulation) and cell volume
manifestly increased compared with the control cells (Fig. 2A).
Real time PCR showed that there was increased expression of
ANP compared with that in control cells ( p < 0.05; Fig. 2B).3.2. Expression of MEF-2 in neonatal rat hypertrophic
cardiomyocytes and effects of drug interventionThe mRNA expression level of MEF-2 was detected by
real-time PCR (Fig. 3). As shown in Fig. 3, expression of
MEF-2 was significantly increased after the stimulation of PE
for 48 hours ( p ¼ 0.027 vs. control). After being treated with
high and medium doses of Lujiao, perindopril, and TSA, the
expression of MEF-2 significantly decreased compared with
that in the PE group, suggesting the role of high and medium
doses of Lujiao in regulating MEF-2. However, there was no
significant change of MEF-2 expression in the low concen-
tration Lujiao group ( p > 0.05 vs. PE group, and p < 0.05 vs.
control group).3.3. Expression of a-MHC mRNA in neonatal rat
hypertrophic cardiomyocyte and effects of drug
interventionCompared with that in the normal control group, the
expression of a-MHC mRNA in the PE group was signifi-
cantly reduced, indicating that the expression of a-MHC
mRNA decreased in rat myocardial cells with myocardial
hypertrophy stimulated by PE. In respect to drug intervention,
expression of a-MHC mRNA was significantly increased in
the groups of medium and high concentration of Lujiao pre-
scription, perindopril, and TSA groups, which was especially
significant in the perindopril group (compared with the PE
group, where p < 0.05). Although the expression of a-MHCwere determined using CAIS-1000 cell imagine analysis system; (B) Real-time
e and after treatment of cells with PE for 48 hours ( p < 0.05), which is used as
trol group; PE ¼ phenylephrine.
Fig. 3. Expression of myocyte enhancer factor 2 (MEF-2) in neonatal rat hypertrophic cardiomyocytes and effects of drug intervention. Methods of myocardial cell
culture and packet processing were conducted. Ten neonate SpragueeDawley rats were soaked in 0.1% bromogeramine. Hearts were collected quickly, and put in
petri dishes containing 5 mL Dulbecco's modified Eagle medium. Western blot was conducted. Primary antibodies against MEF-2 and secondary antibody against
goat-anti mouse-HRP were used. MEF-2 ¼ myocyte enhancer factor 2, PE ¼ phenylephrine. *p < 0.05 vs. control; #p< 0.05 vs. PE.
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tration group, the difference was not statistically significant
(Fig. 4).3.4. Expression of b-MHC mRNA in neonatal rat
hypertrophic cardiomyocyte and effects of drug
interventionCompared with that of the normal control group, the
expression of b-MHC mRNA involved a multifold increase in
myocardial cells of neonatal rats in the PE group, suggesting
that the expression of b-MHC mRNA in the hypertrophic
cardiomyocytes was upregulated. The expression of b-MHC
mRNA in the groups of medium and high concentrations of
Lujiao prescription, perindopril group and TSA group was
dramatically decreased, but it was still higher than that in the
control group (Fig. 5).3.5. Expression of acetylated histone H3 in rat
myocardial cells with drug treatmentWestern blot assay was used in the analysis of acetylated
histone H3 expression in rat myocardial cells with drug
treatment. The acetylation level of histone H3 significantly
decreased in rat myocardial cells stimulated by PE for 48
hours. After treating with different doses of Lujiao prescrip-
tion, perindopril, and TSA, the level of acetylated histone H3
was significantly increased, especially in the high and medium
dose groups (Fig. 6).
4. Discussion
In the process of occurrence and development in relation to
heart failure, myocardial remodeling is one of the most
important basic pathogeneses, and cardiac hypertrophy is one
of the most important pathological processes during theremodeling. Cardiac hypertrophy is of phenomenon whereby
myocardial cell volume increases without cell division, which
is found in many cardiovascular diseases. The biochemical
basis of myocardial cells hypertrophy is the increase of
myocardial protein synthesis, leading to an increase in cell
volume.12 An in vitro myocardial hypertrophy model was
constructed by treating and stimulating cardiac myocytes with
adrenaline or AngII. In the present study, PE stimulation
method was used to establish a myocardial hypertrophy
model.11 There are differences among adrenaline, AngII, and
PE-induced cell models of myocardial hypertrophy. The
reason might be that there could be other mechanisms in the
induced myocardial cell hypertrophy. Another reason might be
that there were conflicting data by different methods in
exploring and detecting myocardial hypertrophy.
In the present study, SD rats were randomly divided into
normal control group, perindopril group, high dose of Lujiao
group, medium dose of Lujiao group and low dose of Lujiao
group. A myocardial hypertrophy model was established by
PE stimulation. HDACs and HATs participate in the myocar-
dial hypertrophy process,10 and regulate downstream hyper-
trophic genes such as cardiac fetal gene by MEF-2. Thus, real-
time PCR and western blotting were used to analyze the
expression of MEF-2, a-MHC, and b-MHC mRNA and the
acetylation level of histone H3. Expression of the MEF-2 gene
was detected in rat myocardial cells with normal growth in the
control group. Furthermore, MEF-2 expression was signifi-
cantly increased and expression of a-MHC mRNA in the PE
group was significantly reduced. Expression of a-MHC and b-
MHC mRNA were significantly increased in the medium and
high concentrations of Lujiao prescription, perindopril, and
TSA groups.
Expression of HDACs was not detected in the present
study, but the TSA intervention after PE stimulation in rat
myocardial cells was used in the analysis. The results showed
that TSA intervention significantly increased the acetylation
Fig. 4. Expression of a-major histocompatibility complex (MHC) mRNA in neonatal rat hypertrophic cardiomyocytes and effects of drug intervention. Methods of
myocardial cell culture and packet processing were conducted. Ten neonate SpragueeDawley rats were soaked in 0.1% bromogeramine. Hearts were collected
quickly, and put in petri dishes containing 5 mL Dulbecco's modified Eagle medium. mRNAwas extracted and real-time polymerase chain reaction was conducted
using a-MHC primers. PE ¼ phenylephrine. *p < 0.05 vs. control, #p < 0.05 vs. PE.
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group, while MEF-2 mRNA expression was downregulated.
The expressions of a-MHC and b-MHC decreased. However,
there was no significant change in the acetylation level of
histone H3 by TSA treatments compared with that of the
normal control group. The acetylation level of histone H3
decreased in rat myocardial cells stimulated by PE for 48
hours. The level of acetylated histone H3 in high concentra-
tions did not increase significantly, while histone H3 acetyla-
tion level in the low concentrations of traditional Chinese
medicine group and perindopril group, and TSA group
increased.Fig. 5. Expression of b-major histocompatibility complex (MHC) mRNA in neonata
myocardial cell culture and packet processing were conducted. Ten neonate Sprag
quickly, and put in petri dishes containing 5 mL Dulbecco's modified Eagle medium
using b-MHC primers. PE ¼ phenylephrine. *p < 0.05 vs. control; #p < 0.05 vs.HDACs and HATs were involved in the myocardial hy-
pertrophy process by MEF-2 responses to hypertrophic gene
downstream (such as cardiac fetal gene) regulation. It is re-
ported that HDACs, as histone deacetylases, inhibited MEF-2
expression, thereby inhibiting cardiac hypertrophy19; HATs
and the histone acetylation and MEF-2 interaction thereby
promoted myocardial hypertrophy. HDACs inhibit MEF-2
expression via histone deacetylase, thus inhibiting cardiac
hypertrophy6; additionally, the HATs promote myocardial
hypertrophy through the histone acetylation and MEF-2
binding.5 It has been established that the histone acetylation
level is increased in the myocardial cell hypertrophy group.l rat hypertrophic cardiomyocytes and effects of drug intervention. Methods of
ueeDawley rats were soaked in 0.1% bromogeramine. Hearts were collected
. mRNAwas extracted and real-time polymerase chain reaction was conducted
PE.
Fig. 6. Expression of acetyl histone H3 in rat myocardial cells with drug treatment. Methods of myocardial cell culture and packet processing were conducted. Ten
neonate SpragueeDawley rats were soaked in 0.1% bromogeramine. Hearts were collected quickly, and put in petri dishes containing 5 mL Dulbecco's modified
Eagle medium. Western blot was conducted to detect expression of histone H3 acetylation. PE ¼ phenylephrine. *p < 0.05 vs. control; #p < 0.05 vs. PE.
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prevent cardiac hypertrophy, inhibit cardiac fetal gene (such as
b-MHC) and ANP activity, increase expression of adult a
visoforms of MHC, and the effect was dose dependent. At the
same time, the total H4 histone acetylation in myocardial cells
increased.20,21 An HDACs inhibitor, TSA, also can signifi-
cantly reduce the myocardial hypertrophy heart coefficient of
homeodomain-only protein-1 transgenic mice and rats induced
by isoproterenol. In addition, the research of Kook22 also
showed HDAC2 could form complex mechanisms with
homeodomain-only protein and inhibited serum response
factor (serum response factor), thereby inhibiting anti-
hypertrophic gene expression. In hypertrophy myocardial
cells, HDACs have double functions of promotion and
antagonist. Our study did not detect the expression of HDACs,
but used the TSA intervention after PE stimulation in rat
myocardial cells. The results showed that TSA intervention
increased significantly the acetylation level of histone H3 in
myocardial cells over those in the model group, while MEF-
2mRNA expression was downregulated. The expressions of
a-MHC and b-MHC decreased. However, there was no sig-
nificant change in acetylation level of histone H3 by TSA
treatments compared with that of the normal control group.Chinese traditional medicine of Lujiao prescription and
perindopril are effective drugs in the treatment of heart failure,
and they have been shown to inhibit left ventricular remodel-
ing.23We established rat cardiac hypertrophy models to explore
the possible mechanism of two kinds of drugs from the angle of
histone acetylation using the method of serum pharmacology.
The experimental results show that compared with that of the
model group, the expression of MEF-2 mRNA and b-MHC
mRNA expression in the high, medium concentration group and
perindopril group all significantly decreased, and the expres-
sion of a-MHC mRNAwas upregulated. At the same time, the
acetylation level of histone H3 increased. The myocardial cell
histone H3 acetylation level was high with Lujiao prescription
intervention compared with that of the normal control group.
This study examined the histone acetylation-MEF-2-a-
MHC/b-MHC axis in myocardial hypertrophy, and interven-
tion results of Lujiao prescription. In fact, many factors can
lead to myocardial cell hypertrophy, the above axis and the
other known signaling pathways such as the relationship be-
tween CaN, MAPK, PKD/HDAC5/MEF2 path to mediate
cardiac hypertrophy still need to be further studied.
The present investigation demonstrates that the combina-
tion of SalB with Rg1, but not with Rb1 alone, demonstrated
493W. Zhao et al. / Journal of the Chinese Medical Association 78 (2015) 486e493significant improvement on cardiac contractility in rats with
myocardial infarction. Unfortunately, Rb1 alone did not
improve the infarct size. The current data indicate that the
histone acetylation-MEF-2ea-MHC/b-MHC axis is found in
myocardial hypertrophy, and the intervention effects of Lujiao
prescription are positive. Because various protein kinases or
signaling proteins such as CaN, MAPK, PKD/HDAC5/MEF2
also contribute to myocardial cell hypertrophy, there is the
possibility that CaN, MAPK, PKD/HDAC5/MEF2 also play
important roles in Lujiao prescription-induced potential ther-
apy for hypertrophic cardiomyocytes. There might be a novel
strategy in therapy for hypertrophic cardiomyocytes by tar-
geting MAPK, PKD/HDAC5/MEF2.
In conclusion, histone acetylation-MEF-2ea-MHC/b-
MHC axis is found in myocardial hypertrophy, and the inter-
vention effects of Lujiao prescription are good.
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